Beacon Therapeutics
Transforming Vision, Transforming Lives
London, United Kingdom · Founded 2023 · $120.0M raised
- Headquarters
- London
- Founded
- 2023
- Website
- beacontx.com
- Total Funding
- $120.0M
- Last Round
- $120.0M Series AJun 2023
- Rounds
- 1
About
Beacon Therapeutics is a leading clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company uses adeno-associated virus (AAV) gene therapy to develop treatments for inherited retinal diseases including X-Linked Retinitis Pigmentosa (XLRP), dry Age-related Macular Degeneration (dAMD), and Cone Rod Dystrophy (CRD). Spun out of Syncona and the University of Oxford in 2023, Beacon raised $120M at launch and an additional $170M Series B to advance its lead candidate laru-zova through late-stage clinical trials. The company operates out of London, UK with facilities in Boston, Massachusetts and Alachua, Florida.
Summary
Beacon Therapeutics is a Biotechnology company based in London, United Kingdom, founded in 2023. It has raised $120.0M in total across 1 round, most recently a $120.0M Series A round in Jun 2023.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2023
Similar Companies
Leading innovative radiopharmaceutical company in China developing next-generation radiopharmaceu...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
Biopharmaceutical company developing multispecific antibody therapies for retinal and complex dis...